<DOC>
	<DOCNO>NCT00302081</DOCNO>
	<brief_summary>This randomize , open-label , multinational study design evaluate `` standard '' regimen , PegIntron 1.5 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg daily [ Arm PEG2b 1.5/R ( 24 week ) ] , compare low dose regimen , PegIntron 1.0 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg daily [ Arm PEG2b 1.0/R ( 24 week ) ] , use 24 week treatment duration arm . Additionally , study examine efficacy reduce treatment duration : PegIntron 1.5 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg 16 week [ Arm PEG2b 1.5/R ( 16 week ) ] .</brief_summary>
	<brief_title>Three Regimens PegIntron Plus Ribavirin Previously Untreated Chronic Hepatitis C , Genotype 2 3 ( Study P03548 )</brief_title>
	<detailed_description>This randomize , open-label , multinational study design evaluate `` standard '' regimen , PegIntron 1.5 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg daily [ Arm PEG2b 1.5/R ( 24 week ) ] , compare low dose regimen , PegIntron 1.0 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg daily [ Arm PEG2b 1.0/R ( 24 week ) ] , use 24 week treatment duration arm . Additionally , study examine efficacy reduce treatment duration : PegIntron 1.5 µg/kg subcutaneously weekly plus ribavirin 800-1200 mg 16 week [ Arm PEG2b 1.5/R ( 16 week ) ] .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>The subject must meet ALL criterion list entry study : Hemoglobin &gt; = 11 g/dL ( female ) ; &gt; = 12 g/dL ( male ) Platelet count &gt; = 100,000/mm^3 Neutrophil count &gt; = 1,500/mm^3 Adult male female chronic hepatitis C ( CHC ) patient ( HCVRNApositive serum ) compensate liver disease ( ChildPugh Score &lt; 7 ) indication treatment accord current consensus guideline ( 1 . NIH Consensus Conference Management Hepatitis C , 2002 ; 2 . German Consensus Conference Hepatitis B C , publish Z Gastro 2004 ; 42 ( 8 ) : 677730 ) . &gt; = 18 = &lt; 70 year age At least one abnormal ALT value last year HCV genotype 2 3 Not previously treat interferon ribavirin alone combination TSH level must within normal limit At Screen Visit , glucose must 70140 mg/dL . Results 116140 mg/dL require repeat fast glucose less than140 mg/dL HbA1C le equal 8.5 % . HbA1C must less equal 8.5 % diabetic subject ( whether medication diet control ) . Female subject pregnant breastfeeding must either postmenopausal , surgically sterile use 2 method birth control . While abstinence sexual activity certain method prevent pregnancy , female patient childbearing potential anticipate possibility become sexually active male partner must use combination follow 2 method : ( 1 ) contraceptive pill IUD depot hormonal preparation ( ring , injection implant ) ; ( 2 ) barrier method contraception diaphragm , sponge spermicide , condom , method birth control consider acceptable study physician . Contraceptive measure review female subject visit . Dual method contraception must use 6 month treatment discontinuation . Sexually active male subject must practice acceptable method contraception ( vasectomy , use condom plus spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 7 month stop treatment Subjects must willing give write informed consent able adhere dose visit schedule . Confirmation principal investigator subinvestigator sexually active female childbearing potential practicing adequate contraception . A serum pregnancy test obtain Screen Visit prior initiation treatment must negative Confirmation principal investigator subinvestigator sexually active male subject practice method contraception consider acceptable ( vasectomy , condom plus spermicide , plus relationship female partner practice acceptable method contraception ) . Contraception must use treatment period seven month ( 6 month , accord local label ) completion therapy , include condom use male subject pregnant partner . For subject history hypertension diabetes , write clearance ophthalmologist obtain prior treatment start Patients young 18 year Patients old 70 year age . Positive AntiHIV antibody Positive HBsAg antibodies Patients severe renal dysfunction creatinine clearance &lt; 50 mL/min must treat PEGIntron Rebetol Pregnant woman , woman plan become pregnant , male subject whose partner want become pregnant , breastfeeding woman . Suspected hypersensitivity interferon ribavirin product . Subject used investigational product within 30 day prior enrollment Subject participate clinical study Any cause liver disease chronic hepatitis C , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Nonalcoholic steatohepatitis ( NASH ) Drugrelated liver disease Active malignant disease suspicion history malignant disease within five previous year ( except adequately treat basal cell carcinoma ) Known coagulation diseases hemophilia ; hemoglobin disease ( e.g . thalassemia ) Known G6PD deficiency Evidence advance liver disease history presence ascites , bleed varix , hepatic encephalopathy . Subjects organ transplant , except corneal hair transplant . Any known preexisting medical condition could interfere subject 's participation completion study , : Preexisting psychiatric condition , especially moderate severe depression , history severe psychiatric disorder , psychosis , suicidal ideation , suicide attempt . Severe depression include follow : hospitalization depression ; electroconvulsive therapy depression ; depression cause prolonged absence work significantly alter daily function . Subjects mild depression may consider entry study provide pretreatment assessment demonstrate subject 's emotional status clinically stable , case management plan must formulate subject ; management plan become part subject 's medical record . Craniocerebral trauma concussion active seizure disorder require medication . Clinically significant ECG abnormality and/or cardiovascular dysfunction within 6 previous month ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) . Chronic lung disease ( e.g. , chronic obstructive lung disease ) Poorly control diabetes mellitus Immunemediated disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ) Clinical gout Subject substance abuser , alcohol ( 80 gm/day ) , methadone , IV , oral inhale drug . To consider inclusion protocol , subject must abstain agree abstain use least 6 month . Subjects treat buprenorphine ( Subutex ) stable 6 month may include Any condition , investigator 's opinion , could determine subject 's participation study indicate could interfere subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Genotype 2 Genotype 3</keyword>
</DOC>